31st Jul 2008 07:00
Vectura Group plc
2007/08 Annual Report and Accounts
Chippenham, UK - 31 July 2008: Vectura Group plc (LSE: VEC), the inhaled product development company, gives notice that copies of its Annual Report and Accounts 2007/08 have been sent to shareholders.
This document is available on the Investor Relations page of the Company's website at www.vectura.com. Copies have also been submitted to the UK Listing Authority for publication through the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS (UKLA telephone helpline: +44 (0) 20 7066 8333).
Further copies of the Annual Report and Accounts 2007/08 are available from the Company Secretary, Vectura Group plc, One Prospect West, Chippenham, Wiltshire, SN14 6FH (telephone number: +44 (0) 1249 667700).
- Ends -
Enquiries:
|
Vectura Group plc |
+44 (0)1249 667700 |
|
Anne Hyland, Chief Financial Officer |
|
|
Julia Wilson, Director of Investor Relations |
|
About Vectura
Vectura Group plc is a product development company focused on the development of a range of inhaled therapies principally for the treatment of respiratory diseases. Vectura develops products to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis, a market which is forecast to double over the next ten years from $23 billion in 2007 to $46 billion by 2017. Vectura also develops products for non-respiratory diseases where optimised delivery via the lungs could provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.
Vectura has eight products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The Company seeks to develop certain programmes further through development to optimise value through licensing at a later stage. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis where this complements Vectura's business strategy.
Vectura has development collaborations with several pharmaceutical companies including Boehringer Ingelheim, Chiesi, Novartis and Sandoz (the generics arm of Novartis). The acquisition of Innovata in January 2007 brought established alliances with a number of additional companies, such as Baxter, GlaxoSmithKline (GSK), Merck Generics (part of Mylan Inc), UCB and Otsuka, as well as providing revenue streams, complementary products and critical mass. For further information, please visit Vectura's website at www.vectura.com
Related Shares:
VEC.L